ArticleJCI insight2019
Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy.
Marco A De Velasco et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
27 papers cite it
this papercites it